^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tyvyt (sintilimab)

    i
    Other names: IBI308, IBI 308, IBI-308, LY-3342901
    Company:
    Eli Lilly, Innovent Biologics, Mankind Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma. (PubMed, Front Immunol)
    A prospective, non-randomized, two-cohort study was designed to evaluate the efficacy of sintilimab combined with chemotherapy in this setting...This preliminary analysis demonstrates that ICI combined with chemotherapy provides durable antitumor activity and a manageable safety profile as neoadjuvant and/or adjuvant therapy for locally advanced PSCC. These results warrant further validation in larger cohorts.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab)
    4d
    Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer. (PubMed, Oncology (Williston Park))
    Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1-positive subgroups, suggesting biomarker-driven therapeutic selection. These findings underscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical insights for personalized treatment strategies.
    Clinical • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    5d
    Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Tyvyt (sintilimab) • capecitabine • Aidixi (disitamab vedotin)
    5d
    NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov)
    P2, N=29, Completed, Guangdong Provincial People's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    6d
    A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=49, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Tumor mutational burden
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • Yervoy (ipilimumab) • Tafinlar (dabrafenib) • Tyvyt (sintilimab)
    7d
    Comparative Retrospective Analysis of Immunotherapy Combined with Anti-Angiogenic Agents and Nab-Paclitaxel in Metastatic Gastroesophageal Junction Adenocarcinoma. (PubMed, Int J Gen Med)
    Patients were divided into two groups: the observation group (sintilimab + apatinib + albumin-bound paclitaxel, n = 42) and the control group (apatinib + albumin-bound paclitaxel, n = 42). The combination of an anti-PD-1 monoclonal antibody with chemotherapy and anti-angiogenic agents demonstrated preliminary efficacy and favorable safety in second-line gastric cancer patients. This study, using real-world data, validates the clinical benefit of this triple regimen, addresses the evidence gap in second-line treatment options, provides new insights for personalized combination strategies in advanced gastric cancer, and holds significant value for guiding clinical practice.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • AiTan (rivoceranib) • albumin-bound paclitaxel
    7d
    Durable progression-free survival with first-line sintilimab plus chemotherapy followed by sintilimab maintenance in PD-L1-high recurrent cervical cancer: a case report. (PubMed, Front Oncol)
    Only grade 2 or lower immune-related adverse events occurred: grade 1 subclinical hyperthyroidism and grade 2 leukopenia. Maintenance therapy with sintilimab after first-line treatment with sintilimab plus chemotherapy can confer substantial clinical benefits in patients with recurrent advanced cervical cancer, with a favorable safety profile and no serious adverse events observed, warranting further prospective investigation.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    Tyvyt (sintilimab)
    8d
    Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=50, Recruiting, Ruijin Hospital
    New P2 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    8d
    Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tyvyt (sintilimab) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • Stivarga (regorafenib)
    14d
    The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients (clinicaltrials.gov)
    P2, N=35, Recruiting, The Third Xiangya Hospital of Central South University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    cisplatin • carboplatin • paclitaxel • Tyvyt (sintilimab)
    14d
    CP-IVX001: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=70, Recruiting, ImmVirx Pty Ltd | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Sep 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Tyvyt (sintilimab) • IVX037
    14d
    A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=276, Recruiting, Fudan University
    New P2 trial • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)